Drug Type Small molecule drug |
Synonyms ES 3000, ES3000 |
Target |
Mechanism CTNNB1 inhibitors(Catenin beta 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 2 | - | - | |
Acute Myeloid Leukemia | Phase 1 | US | 15 Jul 2022 | |
Fibrosis | Preclinical | US | 06 Mar 2024 | |
Fibrosis, Liver | Preclinical | US | 06 Mar 2024 | |
Idiopathic Pulmonary Fibrosis | Preclinical | US | 06 Mar 2024 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | US | - | |
Triple Negative Breast Cancer | Preclinical | US | - |